Galderma Group AG
Study to Evaluate Satisfaction After Treatment With Kysse
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 59
- Registration Number
- NCT03967444
- Locations
- 🇨🇦
Galderma Study Site, Toronto, Canada
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 301
- Registration Number
- NCT03960957
- Locations
- 🇺🇸
Galderma Study Site, Spring, Texas, United States
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT03921411
- Locations
- 🇺🇸
Galderma Investigational Site, Richmond, Virginia, United States
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 47
- Registration Number
- NCT03915860
- Locations
- 🇺🇸
Galderma Investigational Site, Richardson, Texas, United States
A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) Fillers
- Conditions
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 90
- Registration Number
- NCT03869450
- Locations
- 🇬🇧
Galderma Research Site, Edinburgh, United Kingdom
Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 80
- Registration Number
- NCT03780244
- Locations
- 🇺🇸
Galderma Study Site, Spring, Texas, United States
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 401
- Registration Number
- NCT03736928
- Locations
- 🇺🇸
Galderma Research Site, Mequon, Wisconsin, United States
GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 270
- Registration Number
- NCT03700047
- Locations
- 🇺🇸
Galderma study site, Bellaire, Texas, United States
🇺🇸Galderma Study site, Dallas, Texas, United States
🇺🇸Galderma Study Site, Salt Lake City, Utah, United States
Subject Satisfaction With AbobutulinumtoxinA Treatment
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 120
- Registration Number
- NCT03687736
- Locations
- 🇺🇸
Galderma Study Site, Omaha, Nebraska, United States
A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 140
- Registration Number
- NCT03624816
- Locations
- 🇺🇸
Ablon Skin Institute and Research Center, Manhattan Beach, California, United States
🇺🇸Marcus Facial Plastic Surgery, Redondo Beach, California, United States
🇺🇸Wilmington Dermatology and Laser Center, Wilmington, North Carolina, United States